Review
Nature Reviews Cancer 2, 826-835 (November 2002) | doi:10.1038/nrc925
Focus on: Stem Cells
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Shahin Rafii1, David Lyden1,2, Robert Benezra1,2, Koichi Hattori1 & Beate Heissig1 About the authors
Abstract
Tumours recruit neighbouring blood vessels and vascular endothelial cells to support their own blood supply. Recent evidence has indicated, however, that tumours are also capable of mobilizing bone-marrow-derived endothelial precursor cells, inducing them to migrate to the tumour and become incorporated into the developing vasculature. Tumour-derived angiogenic factors promote the recruitment of these cells, which include circulating endothelial progenitor cells and haematopoietic stem and progenitor cells. As clinical trials with anti-angiogenic agents have been confronted with therapeutic hurdles, inhibiting the recruitment of these vascular precursors might provide a novel approach to blocking tumour angiogenesis.
- View At a Glance
Author affiliations
- Division of Hematology-Oncology, Cornell University Medical College, 1300 York Avenue, Room D601, New York, New York 10021, USA.
- Division of Cell Biology of Sloan-Kettering Cancer Institute, New York, New York 10021, USA.
Correspondence to: Shahin Rafii1 Email: srafii@med.cornell.edu
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated NEWS AND VIEWS RESEARCH |
